<?xml version='1.0' encoding='utf-8'?>
<document id="29028125"><sentence text="Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety."><entity charOffset="0-10" id="DDI-PubMed.29028125.s1.e0" text="Ledipasvir" /><entity charOffset="15-24" id="DDI-PubMed.29028125.s1.e1" text="tenofovir" /><entity charOffset="123-132" id="DDI-PubMed.29028125.s1.e2" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.29028125.s1.e0" e2="DDI-PubMed.29028125.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29028125.s1.e0" e2="DDI-PubMed.29028125.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29028125.s1.e0" e2="DDI-PubMed.29028125.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29028125.s1.e1" e2="DDI-PubMed.29028125.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29028125.s1.e1" e2="DDI-PubMed.29028125.s1.e2" /></sentence><sentence text="We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration and estimated glomerular renal function in human immunodeficiency virus-hepatitis C virus coinfected patients receiving a tenofovir-based antiretroviral regimen and treated with ledipasvir/sofosbuvir"><entity charOffset="26-36" id="DDI-PubMed.29028125.s2.e0" text="ledipasvir" /><entity charOffset="45-54" id="DDI-PubMed.29028125.s2.e1" text="tenofovir" /><entity charOffset="205-214" id="DDI-PubMed.29028125.s2.e2" text="tenofovir" /><entity charOffset="261-271" id="DDI-PubMed.29028125.s2.e3" text="ledipasvir" /><entity charOffset="272-282" id="DDI-PubMed.29028125.s2.e4" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e0" e2="DDI-PubMed.29028125.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e0" e2="DDI-PubMed.29028125.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e0" e2="DDI-PubMed.29028125.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e0" e2="DDI-PubMed.29028125.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e0" e2="DDI-PubMed.29028125.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e1" e2="DDI-PubMed.29028125.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e1" e2="DDI-PubMed.29028125.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e1" e2="DDI-PubMed.29028125.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e1" e2="DDI-PubMed.29028125.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e2" e2="DDI-PubMed.29028125.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e2" e2="DDI-PubMed.29028125.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e2" e2="DDI-PubMed.29028125.s2.e4" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e3" e2="DDI-PubMed.29028125.s2.e3" /><pair ddi="false" e1="DDI-PubMed.29028125.s2.e3" e2="DDI-PubMed.29028125.s2.e4" /></sentence><sentence text=" Twenty-six patients [81% male, median age: 51 years; hepatitis C virus genotype 1(75%)/4(15%)] were included" /><sentence text=" Tenofovir trough concentration (interquartile range) increased from 78 ng ml-1 (53-110) at baseline to 141 ng ml-1 (72-176) at 1 month (P = 0"><entity charOffset="1-10" id="DDI-PubMed.29028125.s4.e0" text="Tenofovir" /></sentence><sentence text="003)" /><sentence text=" No significant difference on estimated glomerular renal function using both Cockroft-Gault and Modification of Diet in Renal Disease formulae, respectively, [median (interquartile range)] was observed between baseline [101" /><sentence text="3 ml min-1 (91" /><sentence text="1-114" /><sentence text="1); 95" /><sentence text="6 ml min-1 (86" /><sentence text="5-111" /><sentence text="2)], 1 month [102" /><sentence text="4 ml min-1 (89" /><sentence text="8-112" /><sentence text="9), P = 0" /><sentence text="26; 92" /><sentence text="5 ml min-1 (88" /><sentence text="1-114" /><sentence text="3), P = 0" /><sentence text="27], end-of-treatment [96" /><sentence text="5 ml min-1 (82" /><sentence text="4-115" /><sentence text="4), P = 0" /><sentence text="39; 95" /><sentence text="4 ml min-1 (84" /><sentence text="2-105" /><sentence text="4), P = 0" /><sentence text="16] and 12 weeks after the end of treatment [100" /><sentence text="5 ml min-1 (83" /><sentence text="3-111" /><sentence text="9), P = 0" /><sentence text="24; 93" /><sentence text="4 ml min-1 (82" /><sentence text="2-103" /><sentence text="5), P = 0" /><sentence text="16]" /><sentence text=" Three patients progressed from chronic kidney disease stage 1 to stage 2 at 12 weeks post-treatment" /><sentence text=" A significant increase in tenofovir exposure through P-glycoprotein inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment"><entity charOffset="83-93" id="DDI-PubMed.29028125.s38.e0" text="ledipasvir" /></sentence><sentence text="" /></document>